Review article: steatosis, the metabolic syndrome and cancer

被引:47
作者
Bugianesi, E [1 ]
机构
[1] Univ Turin, Azienda Osped San Giovanni Battista, Div Gastrohepatol, UOADU Gastroepatol, I-10126 Turin, Italy
关键词
D O I
10.1111/j.1365-2036.2005.02594.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The incidence of hepatocellular carcinoma is increasing, but the temporal changes of risk factors remain unclear. A significant proportion of hepatocellular carcinoma (7-30%) develops in cryptogenic cirrhosis, and may represent the most worrisome complication of non-alcoholic steatohepatitis. Non-alcoholic steatohepatitis is tightly related to insulin resistance and several features of the metabolic syndrome, Le obesity, type 2 diabetes and dyslipidaemia. Nearly two-thirds of adults in the United States and an increasing percentage of the population worldwide are overweight or obese. Diabetes prevalence is increasing as well. The rising prevalence of risk factors associated with non-alcoholic steatohepatitis can partially account for the increasing incidence of cryptogenic cirrhosis and subsequent hepatocellular carcinoma. Moreover, recent evidence demonstrates that both obesity and diabetes are per se associated with an increased cancer risk. Large prospective studies show a significant association with obesity for several cancers, including cancers of the colon, female breast, endometrium, kidney, oesophagus and liver (hepatocellular carcinoma). Type 2 diabetes is also related with increased risks of colon, endometrial, kidney, pancreatic cancer and hepatocellular carcinoma. In western countries, the insulin resistance syndrome is emerging as a risk factor for a wide variety of cancers, including hepatocellular carcinoma.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 36 条
[1]
An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis [J].
Alexia, C ;
Fallot, G ;
Lasfer, M ;
Schweizer-Groyer, G ;
Groyer, A .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :1003-1015
[2]
Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? [J].
Bugianesi, E ;
Zannoni, C ;
Vanni, E ;
Marzocchi, R ;
Marchesini, G .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (03) :165-173
[3]
Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].
Bugianesi, E ;
Leone, N ;
Vanni, E ;
Marchesini, G ;
Brunello, F ;
Carucci, P ;
Musso, A ;
De Paolis, P ;
Capussotti, L ;
Salizzoni, M ;
Rizzetto, M .
GASTROENTEROLOGY, 2002, 123 (01) :134-140
[4]
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults [J].
Calle, EE ;
Rodriguez, C ;
Walker-Thurmond, K ;
Thun, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1625-1638
[5]
Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms [J].
Calle, EE ;
Kaaks, R .
NATURE REVIEWS CANCER, 2004, 4 (08) :579-591
[6]
INDUCTION OF APOPTOSIS BY TUMOR-SUPPRESSOR GENES AND ONCOGENES [J].
CANMAN, CE ;
KASTAN, MB .
SEMINARS IN CANCER BIOLOGY, 1995, 6 (01) :17-25
[7]
SELECTIVE SUPPRESSION OF INSULIN-INDUCED PROLIFERATION OF CULTURED HUMAN HEPATOMA-CELLS BY SOMATOSTATIN [J].
CHOU, CK ;
HO, LT ;
TING, LP ;
HU, CP ;
SU, TS ;
CHANG, WC ;
SUEN, CS ;
HUANG, MY ;
CHANG, CM .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (01) :175-178
[8]
Creutzfeldt W, 1970, Prog Liver Dis, V3, P371
[9]
Cause-specific mortality in type 2 diabetes - The Verona Diabetes Study [J].
de Marco, R ;
Locatelli, F ;
Zoppini, G ;
Verlato, G ;
Bonora, E ;
Muggeo, M .
DIABETES CARE, 1999, 22 (05) :756-761
[10]
Di Bisceglie AM, 2003, AM J GASTROENTEROL, V98, P2060, DOI [10.1016/S0002-9270(03)00552-5, 10.1111/j.1572-0241.2003.t01-1-07641.x]